Chinook Therapeutics, Inc.
- Country
- 🇨🇦Canada
- Ownership
- Public, Subsidiary
- Established
- 2019-01-01
- Employees
- 214
- Market Cap
- -
- Website
- http://ww.chinooktx.com
A Study of Zigakibart in Adults With IgA Nephropathy
- Conditions
- IgA NephropathyImmunoglobulin A Nephropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 292
- Registration Number
- NCT05852938
- Locations
- 🇺🇸
University of Alabama at Birmingham: The Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸Vida Medical Centers - Pembroke Pines, Pembroke Pines, Florida, United States
🇺🇸Cleveland Clinic-9500 Euclid Ave, Cleveland, Ohio, United States
Open-label Safety and PK Study of BION-1301 in Japanese Healthy Subjects
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05508204
- Locations
- 🇺🇸
Collaborative Neuroscience Research, LLC, Long Beach, California, United States
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT05367661
- Locations
- 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
Atrasentan in Patients With IgA Nephropathy
- Conditions
- IgA NephropathyImmunoglobulin A Nephropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 404
- Registration Number
- NCT04573478
- Locations
- 🇺🇸
Liberty Research Center, Dallas, Texas, United States
🇨🇳The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
🇨🇳Peking University People's Hospital, Beijing, China
Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)
- Conditions
- Multiple Myeloma
- Interventions
- Biological: BION-1301
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT03340883
- Locations
- 🇺🇸
James R. Berenson, MD, Inc, West Hollywood, California, United States
🇺🇸Winship Cancer Institute/Emory University, Atlanta, Georgia, United States
🇺🇸Ohio State University Wexner Medical Center James Cancer Hospital, Columbus, Ohio, United States